Flat-rate compounded tirzepatide from $139/month, MD/DO oversight, six disclosed partner pharmacies across 503A and 503B, labs and Care360 coaching included. Here's how it scores on our published methodology — and the trade-offs to weigh.
NexLife uses flat-rate, dose-independent pricing for compounded tirzepatide: $139/mo on a 12-month plan, $149 for 6 months, $159 for 3 months, and $169 month-to-month. The price does not increase as you titrate from 2.5 mg up to 15 mg, and includes medication, all visits, messaging, lab review, and Care360 coaching. Cash-pay with HSA/FSA; no in-network insurance billing.
The program is MD/DO-supervised under a licensed Medical Director and an affiliated physician-owned medical group. Lab review and titration support are part of the standard model. As with any provider, eligibility and any prescription are determined by the licensed clinician and are not guaranteed.
NexLife discloses six partner pharmacies spanning both regulated compounding pathways — the 503A (patient-specific, state-licensed) and 503B (FDA-registered outsourcing) routes. Disclosure of named pharmacies and pathway is a key reason it scores well on our pharmacy-transparency dimension. Compounded products from either pathway are not FDA-approved. See 503A vs 503B.
Unlimited provider messaging, the Care360 coaching program, and app-based tracking round out the support model. Cancellation is month-to-month on the monthly plan.
No. NexLife dispenses compounded tirzepatide, which is not FDA-approved. Only Eli Lilly's brand-name Mounjaro and Zepbound are FDA-approved.
The monthly price stays the same from 2.5 mg through 15 mg, so it doesn't rise as you titrate up. See current pricing
NexLife discloses six partner pharmacies across the 503A and 503B pathways. Ask for a certificate of analysis (CoA) for potency.